메인비쥬얼

R&D Area Humedix grows into a global health care company

컨텐츠

Volumizing Filler, PDRN & Addition of new indication

Product Serialization

One-shot formulation joint injection (HUMIA 14002)

One-shot formulation joint injection - Improved convenience through reduction of administration frequency and expected profit creations such as technology export etc.

Leuprorelin depot

Leuprorelin depot for 1 month - Improvement of convenience through reduction of administration frequency, expansion of indications (anti-cancer effect)

Advanced HA Crosslink technology

Development of HI new cross-linking method - Minimization of side effect by cross-linking agent reduction, minimization of non-crosslinking reaction (Pendant), maximization of cross link ratio

HA Biphasic filler

HA biphasic filler – Application of new cross link method, securing Filler and mono / biphasic full line that minimizes side effects

- Korea's first monophasic and biphasic full-line products
- Development of a high viscoelastic biphasic filler that solves the problem caused by the fluidity of HA gel particles due to the low viscosity, which is a disadvantage of existing biphasic filler

Active material

Development of HI new cross-linking method - Minimization of side effect by cross-linking agent reduction, minimization of non-crosslinking reaction (Pendant), maximization of cross link ratio

Cosmetic material & Formulation technology development